Most “AI predicts disease” papers don’t survive a second read. This one does, and it points at a kind of heart risk your echo was never built to see. I’ve spent my whole career in machine learning, so I read the steady drip of “AI predicts your death” headlines the way a mechanic reads ads
I take two drugs that would get an Olympian banned: testosterone and a GLP-1. I will never compete, so the only thing they enhance is my ability to climb stairs and lift a barbell after 50. Here is what they actually do, and what they don’t.
My friend is sober, goes to AA, and just started the Wegovy pill for the cravings that never left. Here is what ninety years of alcohol treatment, from the Twelve Steps to a GLP-1, actually shows.
Lunchables was engineered inside Philip Morris using the cigarette playbook. That part is real and damning. The case that ultra-processed food is poison is shakier, and both can be true at once.
BPC-157 promises what an aging body wants most: faster healing, less pain, a return to the version of you that bounced back. It has almost no human evidence behind it. People are sure it works anyway, and in July an FDA committee votes on whether to let pharmacies make it.
Retatrutide isn’t FDA approved, but it has a street name, a grey market with customer service, and Wall Street’s full attention. What the strongest weight-loss drug ever tested means, and why I’m not taking it.
A new study found people on GLP-1 drugs took fewer steps after starting. I lost the weight and moving got easier, so I went looking for why most people slow down.
I grew up around cigarettes in Germany and watched them vanish. Bans, taxes, and warning labels on sugary drinks all work differently, and what separates them is not how much soda drops. It is who they reach.
Two dozen outlets ran the same glucosamine-Alzheimer’s scare in four days. The new Nature Metabolism paper is strong mouse biology with a weak hospital-records footnote, and the bigger human data points the other way.
A 147,000-person, 30-year Harvard study gives a rough number for the strength-training half of the exercise guideline: around 90 to 120 minutes a week, and it pairs with walking better than it replaces it.
